Compare GXO Logistics Inc (GXO) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GXO Logistics Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? GXO Logistics Inc trades at $47.96 (market cap $5.37B), while Vertex Pharmaceuticals Incorporated trades at $529.5 (market cap $134.25B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 25× GXO Logistics Inc's market cap, and Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, GXO Logistics Inc nearer its low. Which is the better fit depends on your goals.
| GXO | VRTX | |
|---|---|---|
Market Cap | $5.37B | $134.25B |
Sector | Industrials | Health |
52-Week High | $65.59 | $529.65 |
52-Week Low | $45.52 | $376.62 |
Enterprise Value | $10.72B | $128.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GXO Logistics trades at $47.85, up 1.9% in the last session, with a bearish technical signal but strong analyst backing. The stock shows consistent earnings beats, with Q2 2026 EPS of $0.59 exceeding expectations, and revenue growth to $13.6 billion in 2026. However, margins remain tight, with a net income margin of 0.96%, and the P/E ratio of 41.3 suggests high valuation relative to earnings.
The outlook is mixed: bullish analyst consensus, with 88.9% buy ratings and a $65.67 price target, indicates potential upside, but stagnant margins and bearish technicals pose risks. Investors should weigh strong business wins against cost absorption challenges highlighted in recent earnings reports.
Vertex Pharmaceuticals (VRTX) trades at $526.33, up 0.46% on the day, with a bullish technical outlook supported by moving averages. The stock shows strong fundamentals with 2025 revenue of $12.0B and net income of $3.95B, though recent Q2 2026 earnings slightly missed estimates. Analyst sentiment remains positive with an 83.9% buy rating and a $534.25 consensus price target, while news highlights raised 2026 sales guidance driven by cystic fibrosis drug strength and newer product launches.
The outlook for VRTX is favorable given robust revenue growth, high profitability margins, and raised full-year guidance. Key opportunities include diversification beyond cystic fibrosis with newer products, but risks involve earnings volatility, competitive pressures, and execution on pipeline developments. The stock's valuation at a P/E of 30.85 requires sustained growth to justify further upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GXO Logistics Inc
GXO is the world's largest pure-play contract logistics provider. It offers cutting-edge supply chain solutions, including automated warehousing and fulfillment, for global blue-chip companies.
Read more on GXO →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
